(RTTNews) - Shares of Recursion Pharmaceuticals, Inc. (RXRX) are trading down on Thursday morning after surging to a year-to-date high on yesterday after announcing a collaboration and $50 million ...

Recursion Pharmaceuticals (NASDAQ:RXRX) announces the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at $6.50 a share, for an expected gross proceeds of ...

Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date. The clinical stage ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

Recursion’s presentation emphasized its differentiated approach compared to traditional biotech companies. While conventional biotechs typically advance one program at a time through a linear ...

I last covered Recursion Pharmaceuticals (NASDAQ:RXRX) for Seeking Alpha back in February, when I gave the company's stock a "HOLD" rating and suggested that the company was "not yet derisking drug ...